THYTECH is a spin-off of the Gregorio Marañón Health Research Institute (IISGM) that was created with the aim of transferring to the patient our patented technology for the treatment of diseases related to immune disorders.
The company arises from the work carried out by the researchers of the Immunoregulation Laboratory, and our main asset is a cellular therapy with thyTreg cells that is pioneering in the world that can establish a new paradigm in the prevention of transplant rejection and in the treatment of autoimmune diseases and clinical worsening of COVID patients.

Description

People (2)

Jobs (0)

Other offices